Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
HUM enters the final stretch before its November 6 earnings with analyst sentiment shifting meaningfully in its favour, a sharp contrast to the cost-pressure narrative that dominated the stock for much of the year.
The catalyst this week was a Cantor Fitzgerald upgrade from Neutral to Overweight, with analyst Sarah James lifting her target from $300 to $460, filed this morning. That follows a similar move from Barclays two weeks ago, when Andrew Mok upgraded to Overweight with a $515 target, up from $407. Both actions are notable: they represent a genuine change of direction from firms that were sceptical, not a reiteration from existing bulls. The broader analyst picture has shifted to 12 buys against 11 holds, with the mean price target at $431, around 6.5% above the current price of $404. JPMorgan remains at Neutral, and Raymond James downgraded to Market Perform after the July results, keeping a lid on the full consensus. Still, the direction of travel among upgrades is clearly upward, and targets have moved sharply higher since Q2 results landed in late July.
The bull case centres on Medicare Advantage margin recovery. Group MA margin expanded 500 basis points, reflecting better contract renegotiation outcomes, and CenterWell's pharmacy arm grew revenue 16%. Forward EPS estimates are pricing in a roughly 185% year-on-year increase, and Humana ranks in the 92nd percentile on 90-day EPS momentum and the 94th percentile on analyst recommendation divergence, both suggesting the Street is more constructive than its positioning implied a quarter ago. The bear case is harder to dismiss, though. The company still faces an estimated $3.5 billion headwind from declining MA Star ratings, which analysts have flagged as a roughly $22 drag on 2026 EPS. Competitive pressure in Medicare Advantage is intensifying, and reimbursement rates remain a structural concern. The PE multiple is at 27.2x, having pulled back around one point over the past month, while EV/EBITDA has drifted to 15.3x over the same period, modest compression even as the stock gained 4.5% this week.
The lending market gives shorts no particular advantage here. Borrow availability is extraordinarily loose, with roughly 79 times as many shares available to borrow as are currently short. Cost to borrow has eased nearly 24% this week to around 0.34%, among the lowest readings in the 30-day window. Short interest is just 2.4% of the free float, down from around 3.4% six weeks ago, a clear reduction in bearish conviction. The options market is also fairly composed: the put/call ratio is at 0.998, only fractionally above its 20-day average of 0.976 and half a standard deviation away. That is not the kind of defensive positioning that typically precedes a heavily contested earnings print, even with the stock down nearly 5.7% on the day of its last results in late July.
That July reaction is worth noting. HUM fell 5.7% on the day and 6.4% over the five sessions that followed, suggesting the market is capable of punishing the stock even when the headline print appears constructive. Close peers have had a mixed week: CNC gained 3.9% and ASTH rose 4.4%, broadly in line with HUM, while CVS and CI both dipped slightly. UNH was little changed. The sector move looks supportive rather than idiosyncratic, which reduces the signal from HUM's weekly gain on its own.
Capital Research and Management added over 1.35 million shares in the most recent reported period, one of the larger incremental positions among top holders. BlackRock and JP Morgan Asset Management also added modestly. Dodge and Cox remains the largest disclosed holder at around 9.1% of shares. The 13D/G register carries no activist position, and all filings are passive Schedule 13G disclosures. Insider activity over the past 90 days consists entirely of grant-type transactions (code A), with no open-market purchases or sales, so the insider register adds no directional signal here.
With earnings 30 days out, the question is whether the upgrade cycle has run ahead of the fundamental improvement or whether the Star ratings drag has been sufficiently priced in at current levels.
See the live data behind this article on ORTEX.
Open HUM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
